407 related articles for article (PubMed ID: 23356031)
1. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
5. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
7. Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
Silva IM; Oliveira CA; Guedes WR; Oliveira BB; Oliveira DA; Guedes Filho G
Braz J Infect Dis; 2009 Apr; 13(2):158-60. PubMed ID: 20140364
[TBL] [Abstract][Full Text] [Related]
8. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
9. Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
[TBL] [Abstract][Full Text] [Related]
10. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
11. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
13. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
[TBL] [Abstract][Full Text] [Related]
14. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
Goulart IM; Arbex GL; Carneiro MH; Rodrigues MS; Gadia R
Rev Soc Bras Med Trop; 2002; 35(5):453-60. PubMed ID: 12621663
[TBL] [Abstract][Full Text] [Related]
15. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
[No Abstract] [Full Text] [Related]
16. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
[TBL] [Abstract][Full Text] [Related]
17. Multidrug therapy (MDT) and leprosy control.
Noordeen SK
Indian J Lepr; 1990; 62(4):448-58. PubMed ID: 2086680
[No Abstract] [Full Text] [Related]
18. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
Andrade VL; Marques AB; da Cunha LH; Avelleira JR
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
[TBL] [Abstract][Full Text] [Related]
20. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]